BEHAVIORAL
NutriAct plus
Dietary pattern, vegetarian version of the NutriAct pattern
Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?
Status
Not yet recruiting
Phase
Not applicable
Enrollment
292
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy. This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.
Interventions
Treatment arms and agents.
BEHAVIORAL
Rescue VLCD
Very low calorie diet as full meal replacement over 28 days in case of weight regain
Timeline
From registration to results.
First posted
Jul 17, 2026
Study start
Mar 2027
Primary completion
Feb 2030
Study completion
Apr 2030
Results posted
Not reported
Registry updated
Jul 20, 2026
Outcomes
What the study measures.
Primary outcomes
weight in kg
Time frame · body weight in kg after weight loss (3 to 5 months) and dietary intervention (12 months)
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * BMI ≥ 30 kg/m² OR ≥ 27 kg/m² with concomitant cardiometabolic risk factors (metabolic syndrome, elevated blood pressure, dyslipidemia or impaired glucose metabolism (but not type 2 diabetes) Exclusion Criteria: * BMI ≥ 45 kg/m² * intake of glucose lowering drugs * presence of incretin-based treatment * acute severe CVD * uncontrolled hypertension * severe hepatic or renal diseases * severe food allergy or malabsorption disease * active cancer * condition after bariatric surgery * history of eating disorder * concurrent pregnancy and breastfeeding
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Semaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Imperial College London · Pulmonary Arterial Hypertension
Phase 2
Not yet recruiting
32
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.